The fill-finish site will produce both autoinjectors and pre-filled syringes – serving Roche’s pipeline and portfolio.

Roche Holding stock has delivered a 58.5% return over the past three years, yet the current valuation checks give a more mixed read on how much upside may be left in the price. Roche Holding's 58.5% three year return highlights that shareholders have already seen solid gains, so fresh buyers need to think carefully about what is now priced in. Large ongoing investments in U.S. manufacturing facilities and collaborations in diagnostics can support expectations for future cash flows, while the...

ADI targets multiyear AI growth as data center power and optics surge, with Q4 guidance signaling momentum into fiscal 2027 and broader recovery.

You do not expect a pharmaceutical giant with a $376 billion market cap to put up numbers that make growth investors blush. Yet over the last 12 months, Merck (MRK) handed investors an 80% return, lapping the S&P 500. The apex occurred yesterday, August 19, 2026, when the stock surged to all-time highs.

By Mike Sheikh Parkinson’s Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate. The market isn’t recognizing the story yet with its paltry market cap of $5.0M, and that disconnect has created a sizable opportunity for investors for a future rerating. […] The post Real Parkinson’s Disease Hope from Jupiter Neurosciences appeared first on ExecEdge.

Recursion Pharmaceuticals (NASDAQ:RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and support collaborations with larger pharmaceutical companies, CFO and President of Recursion U.K. Ben Tayl

They are fairly risky, but their potential upside is massive.

GDP grew at its fastest quarterly pace since 2021, but the boom may say more about drug exports than a broad national sprint.

MRK's Keytruda remains a key growth engine in 2026, but patent loss and rising competition could challenge its long-term sales momentum.

Labcorp Holdings (LH) is in focus after a series of oncology diagnostics approvals and launches, including the PGDx elio tissue complete CDx for advanced melanoma and nationwide access to Roche's VENTANA PTEN RxDx Assay for prostate cancer. See our latest analysis for Labcorp Holdings. Labcorp Holdings has attracted more attention in recent months, with oncology diagnostics approvals and stronger earnings updates sitting alongside a 30 day share price return of 16.48% and a 1 year total...

Moby summary of Seer, Inc.'s Q2 2026 earnings call

In late July and early August 2026, Labcorp reported higher second-quarter and year-to-date earnings, raised its 2026 revenue growth guidance, completed a large share repurchase program, and expanded its precision oncology offering by making Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay available nationwide to help guide prostate cancer treatment decisions. Together with the recent FDA approval of its PGDx elio tissue complete CDx for advanced melanoma, these developments reinforce...

Roche Holding now sits on a refreshed fair value estimate of CHF 370.31, up from CHF 359.22. This gives you an updated reference point for where analysts see the stock’s long term potential. This move lines up with recent research that highlights contrasting views on the company’s pipeline, from optimism around giredestrant and 2027 catalysts to more cautious takes on how much upside is already captured in forecasts. Read on to see how these shifting assumptions shape the evolving narrative...

Regeneron's Eylea HD and Dupixent strength are fueling growth, while oncology gains and pipeline progress support its outlook.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimiza

Morgan Stanley made Roche a Top Pick as giredestrant approaches two pivotal FDA decisions and a potential U.S. launch.

Prothena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner pipeline progress as a key milestone decision nears.

HALO's Q2 earnings and revenues surpass estimates, fueled by higher royalties and product sales. The company raises its 2026 outlook.

BMS is the latest major drugmaker to tap Nvidia for more computing power, betting that larger models and AI agents can speed drug discovery.

SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.

Exelixis beats EPS estimates but misses on revenues; cuts 2026 outlook as a slower-than-expected NET launch weighs on expectations.

Recursion misses Q2 earnings and revenue estimates as collaboration revenues fall year over year, sending shares lower while pipeline and partnership programs advanced.

The healthcare company has introduced two new research-use PCR tests as demand for cyclospora detection grows during an ongoing U. S.

Roche Holding (SWX:ROP) has entered a clinical collaboration with Evexta Bio to test a combination of rupitasertib and giredestrant. The partnership focuses on a Phase 1b trial in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer. The agreement centers on a breast cancer segment with significant unmet medical need. Roche Holding, traded as SWX:ROP, is adding this collaboration to an oncology portfolio that already plays a central role in the company’s identity. The stock...

Nurix Therapeutics (NasdaqGM:NRIX) announced a $10 million milestone payment tied to the first in human trial of an oral STAT6 degrader in its collaboration with Sanofi. The company also reported enrollment of the first patient in a pivotal global Phase 3 trial of bexobrutideg for relapsed or refractory chronic lymphocytic leukemia in partnership with Roche. Both programs advance Nurix's clinical pipeline in targeted protein degradation and expand its work with large pharmaceutical...

IDEAYA Biosciences recently reported a second-quarter 2026 net loss of US$112.45 million, or US$1.22 per basic and diluted share, while also disclosing a wider six‑month loss versus the prior year. In parallel, IDEAYA advanced its precision oncology pipeline by initiating Part 2 monotherapy expansion for IDE892 and entering a clinical collaboration with Roche to explore combination regimens in MTAP‑deleted pancreatic cancer, an area with significant unmet medical need. With IDE892’s...

The planned trial aims to enrol at least 15 participants and is expected to begin in the fourth quarter of 2026.